Clinical Trial Detail

NCT ID NCT03093870
Title Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Aslan Pharmaceuticals
Indications

ampulla of Vater carcinoma

cholangiocarcinoma

gallbladder cancer

biliary tract cancer

Therapies

Capecitabine + Varlitinib

Capecitabine

Age Groups: child adult senior

No variant requirements are available.